2023
Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a meta-analysis of randomized trials
Ahmad Y, Howard J, Arnold A, Madhavan M, Cook C, Alu M, Mack M, Reardon M, Thourani V, Kapadia S, Thyregod H, Sondergaard L, Jørgensen T, Toff W, Van Mieghem N, Makkar R, Forrest J, Leon M. Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a meta-analysis of randomized trials. European Heart Journal 2023, 44: 836-852. PMID: 36660821, DOI: 10.1093/eurheartj/ehac642.Peer-Reviewed Original ResearchConceptsSurgical aortic valve replacementTranscatheter aortic valve implantationHigh-risk patientsLow-risk patientsComposite of deathAortic valve replacementValve replacementMAIN OUTCOMENew-onset atrial fibrillationSignificant differencesRandomized clinical trial dataAcute kidney injuryAortic valve implantationMain clinical outcomesRisk of deathClinical trial dataMajor bleedingKidney injurySecondary endpointsVascular complicationsValve implantationClinical outcomesParavalvular leakRandomized trialsAtrial fibrillationPublic Reporting of Stroke After Transcatheter Aortic Valve Replacement A Cautionary Tale ∗
Lansky A, Ahmad Y. Public Reporting of Stroke After Transcatheter Aortic Valve Replacement A Cautionary Tale ∗. JACC Cardiovascular Interventions 2023, 16: 177-178. PMID: 36697153, DOI: 10.1016/j.jcin.2022.11.010.Peer-Reviewed Original Research
2022
Mechanical thrombectomy with retrievable stents and aspiration catheters for acute ischaemic stroke: a meta-analysis of randomised controlled trials.
Rajkumar CA, Ganesananthan S, Ahmad Y, Seligman H, Thornton GD, Foley M, Nowbar AN, Howard JP, Francis DP, Keeble TR, Grunwald IQ, Al-Lamee RK, Malik I, Shun-Shin MJ. Mechanical thrombectomy with retrievable stents and aspiration catheters for acute ischaemic stroke: a meta-analysis of randomised controlled trials. EuroIntervention 2022, 17: e1425-e1434. PMID: 34503942, PMCID: PMC9896406, DOI: 10.4244/eij-d-21-00343.Peer-Reviewed Original ResearchConceptsSymptomatic intracranial hemorrhageAcute ischemic strokeModified Rankin ScaleIschemic strokeCause mortalityMechanical thrombectomyAspiration catheterIntracranial hemorrhageRetrievable stentsAnterior circulation ischemic strokeLong-term neurological outcomeAcute anterior circulation strokeTrial of thrombectomyAnterior circulation strokeStandard of careIntravenous thrombolysisNeurological outcomeSecondary endpointsPrimary endpointSubsequent disabilityMRS scoreRankin ScaleMedical therapyThrombectomyTreatment strategies
2018
Reply to: Assessing the quality of evidence supporting patent foramen ovale closure over medical therapy after cryptogenic stroke
Ahmad Y, Howard J, Arnold A, Shun-Shin M, Cook C, Francis D, Sen S. Reply to: Assessing the quality of evidence supporting patent foramen ovale closure over medical therapy after cryptogenic stroke. European Heart Journal 2018, 39: 3620-3620. PMID: 30137277, DOI: 10.1093/eurheartj/ehy498.Peer-Reviewed Original ResearchPatent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials
Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, Demir O, Williams L, Iglesias JF, Sutaria N, Malik I, Davies J, Mayet J, Francis D, Sen S. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. European Heart Journal 2018, 39: 1638-1649. PMID: 29590333, PMCID: PMC5946888, DOI: 10.1093/eurheartj/ehy121.Peer-Reviewed Original ResearchConceptsMedical therapyCryptogenic strokeDevice closurePFO closureAtrial fibrillationRecurrent strokeLarge shuntPatent foramenNew-onset atrial fibrillationRisk of AFOnset atrial fibrillationPrimary safety endpointPrimary efficacy endpointAtrial septal aneurysmPrevention of strokeSignificant reductionEfficacy endpointFurther strokeSafety endpointTreat basisSeptal aneurysmSmall shuntPatientsTherapyStroke
2015
A new method of applying randomised control study data to the individual patient: A novel quantitative patient-centred approach to interpreting composite end points
Ahmad Y, Nijjer S, Cook CM, El-Harasis M, Graby J, Petraco R, Kotecha T, Baker CS, Malik IS, Bellamy MF, Sethi A, Mikhail GW, Al-Bustami M, Khan M, Kaprielian R, Foale RA, Mayet J, Davies JE, Francis DP, Sen S. A new method of applying randomised control study data to the individual patient: A novel quantitative patient-centred approach to interpreting composite end points. International Journal Of Cardiology 2015, 195: 216-224. PMID: 26048380, DOI: 10.1016/j.ijcard.2015.05.109.Peer-Reviewed Original ResearchConceptsIndividual patientsComposite end pointCoronary artery bypassDrug-eluting stentsPatient-centered approachSignificant differencesPatient preference dataPatient-centered metricsArtery bypassCardiac catheterisationComposite endpointPatient preferencesPatientsTrial dataEnd pointTrial resultsEndpointMACECABGSurgeryTrialsStructured toolDeathStudy dataRevascularisation
2013
Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review Of Cardiovascular Therapy 2013, 11: 1029-1049. PMID: 23984927, DOI: 10.1586/14779072.2013.815423.Peer-Reviewed Original ResearchConceptsStroke preventionAntithrombotic therapyAntithrombotic agentsNovel oral anticoagulation agentsAtrial fibrillation guidelinesOral anticoagulation agentsDrug-drug interactionsDirect antidoteAF patientsAnticoagulation monitoringAnticoagulation agentsAtrial fibrillationAbsolute riskAntithrombotic pharmacotherapyRelative riskLower riskStrong recommendationsPatientsThromboembolismPreventionRiskTherapyInherent risksAuthors' knowledgeAgentsRecent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke
Ahmad Y, Lip GY, Lane DA. Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke. Canadian Journal Of Cardiology 2013, 29: s4-s13. PMID: 23790597, DOI: 10.1016/j.cjca.2013.03.009.Peer-Reviewed Original ResearchConceptsDevelopment of AFAtrial fibrillationRisk factorsStroke riskAF patientsOccurrence of AFEffective oral anticoagulationAcute cardiac conditionsCause of strokeLow-risk patientsNovel risk factorsNovel therapeutic targetPublic health consequencesFormal anticoagulationOral anticoagulationRisk patientsPatient cohortCardiac conditionsEpidemic proportionsTherapeutic targetClinical practicePatientsAnticoagulationHealth consequencesRisk determinantsWarfarin for stroke prevention in atrial fibrillation: time to switch?
Ahmad Y, Lip G. Warfarin for stroke prevention in atrial fibrillation: time to switch? International Journal Of Clinical Practice 2013, 67: 603-605. PMID: 23758442, DOI: 10.1111/ijcp.12157.Peer-Reviewed Original ResearchPreventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation
Ahmad Y, Lip GY. Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation. Contributions To Nephrology 2013, 179: 81-91. PMID: 23652451, DOI: 10.1159/000346726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineClinical Trials as TopicComorbidityDabigatranDisease ManagementEmbolismFemaleFibrinolytic AgentsHemorrhageHumansHypertensionIntracranial EmbolismMaleMorpholinesPatient SelectionPyrazolesPyridonesRenal Insufficiency, ChronicRiskRisk FactorsRivaroxabanSeverity of Illness IndexStrokeThiophenesThrombophiliaWarfarinConceptsSevere renal impairmentAtrial fibrillationRisk factorsGeneral populationRenal impairmentRenal diseaseRenal patientsAbsence of AFLarge randomised control trialBenefits of warfarinNew oral anticoagulantsChronic kidney diseaseCohort of patientsRisk of strokeRandomised control trialEctopic vascular calcificationMajority of trialsUnique management challengesAF independentSystemic embolismOral anticoagulantsRenal insufficiencyStroke preventionThromboembolic riskStroke riskGone Fishing (for Silent Atrial Fibrillation)
Ahmad Y, Kirchhof P. Gone Fishing (for Silent Atrial Fibrillation). Circulation 2013, 127: 870-872. PMID: 23439445, DOI: 10.1161/circulationaha.112.000985.Peer-Reviewed Original Research
2012
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation
Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Review Of Cardiovascular Therapy 2012, 10: 1471-1480. PMID: 23253272, DOI: 10.1586/erc.12.148.Peer-Reviewed Original ResearchConceptsNew oral anticoagulantsParoxysmal atrial fibrillationOral anticoagulantsNonparoxysmal atrial fibrillationAtrial fibrillationHeart failureStroke preventionNew anticoagulantsContemporary phase III trialsAdditional prognostic benefitPhase III trialsPresence of diabetesNew drugsImpact of genderIII trialsPrognostic benefitDiabetes mellitusAnticoagulantsPatientsWarfarinEvent ratesCardiovascular medicineFibrillationMellitusDiabetesStroke Prevention in Atrial Fibrillation: Concepts and Controversies
Ahmad Y, Lip G. Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. Current Cardiology Reviews 2012, 8: 290-301. PMID: 22920480, PMCID: PMC3492813, DOI: 10.2174/157340312803760820.Peer-Reviewed Original ResearchConceptsStroke risk factorsAtrial fibrillationOral anticoagulationStroke preventionRisk factorsPatient riskIndependent stroke risk factorNew oral anticoagulantsCommon cardiac rhythm disorderLow-risk patientsCardiac rhythm disordersAntiplatelet therapyAntithrombotic therapyOral anticoagulantsSevere strokePerioperative managementEffective therapyRhythm disordersEfficacious agentsGeneral populationNew agentsSimple scorePatientsAnticoagulationFibrillationDabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance
Ahmad Y, Lip GY. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart 2012, 98: 1404. PMID: 22698856, DOI: 10.1136/heartjnl-2012-302101.Peer-Reviewed Original Research